Chairs: M.S. Aapro, CH - J. Gligorov, FR
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This conference, organized for several years, aims to take stock of current and future tools that help us optimize the care of patients with cancer.
• Update the knowledge of the implications for practice and clinical research (tools to be used, tools still in research, areas where no tools are yet available)
• Understanding epigenetics and genomics research and their impact on cancer prognosis and therapy response (prediction)
• Lung cancer
• Colorectal cancer
• Prostate cancer
• Breast cancer
Programme and organisation
European School of Oncology (ESO)
Piazza Indipendenza 2
ph +41 91 820 09 58
Programme and registrations
Tel: +41 91 820 09 51
Radisson Blu ES. Hotel
Via Turati, 171
Phone: +39 06 444 841
Travel grants were made available on a competitive basis. The application deadline is passed (28 August).
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.
The official language will be English. No translation will be provided.
The organisers bear no responsibility for untoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance.
CME ACCREDITATION AND CERTIFICATES
Participants will be entitled to receive a certificate of attendance at the close of the Conference by completing the online evaluation questionnaire.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value. The event is designated for a maximum of 9 European CME credits (ECMEC). Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Furthermore, for Italian participants, a maximum of 10 ECM credits have been granted by Commissione Nazionale per la Formazione Continua.
More information can be obtained from the organizing secretariat.
REGISTRATION DESK, OPENING HOURS
Friday, 25 November 8:00-18:00
Saturday, 26 November 8:00-13:00
EXHIBITION, OPENING HOURS
Friday, 25 November (9:00-18:00)
Saturday, 26 November (8:00-13:30)
ESO wishes to extend its appreciation to Genomic Health for having granted its participation and support to the conference.
M.S. Aapro, IMO Clinique de Genolier, CH
D. Arnold, CUF Hospitals Cancer Center, Lisbon, PT
L. Crinò, University of Perugia, Perugia, IT
G. Curigliano, European Institute of Oncology, Milan, IT
R. Danesi, University of Pisa, Pisa, IT
L. Del Mastro, Istituto Nazionale per la Ricerca sul Cancro, Genoa, IT
V. Dieras, Institut Curie, Paris, FR
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
J. Gligorov, Hopitaux Universitaires Paris Est Tenon, Paris, FR
U. Malapelle, University Federico II of Naples, IT
N. Mottet, Hopital Nord, Saint Etienne, FR
N. Normanno, INT-Fondazione Pascale, Naples, IT
F. Penault-Llorca, Centre Jean Perrin, Clermon-Ferrand, FR
J. Remon, Vall d'Hebron University Hospital, Barcelona, ES
J. Robert, Universitè Bordeaux Segalen, Bordeux, FR
E. Rouleau, Institut Gustave Roussy, Villejuif, FR
A. Stathis, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
D. Tilki, University Hospital Hamburg-Eppendorf - Martini Klinik, Hamburg, DE
G. Viale, European Institute of Oncology, Milan, IT
|9:45||Welcome and introduction
M.S. Aapro, CH - J. Gligorov, FR
|10:00||Understanding drivers of cancer cell development|
U. Malapelle, IT
|10:30||Understanding next generation sequencing
|R. Rouleau, FR
|11:00||Understanding liquid biopsies
|R. Danesi, IT
|11:30||Understanding pharmacogenetics in cancer treatment and clinical trials
|J. Robert, FR
Round table and discussion
|WHERE DO WE STAND ON LUNG CANCER?
|13:30||Lung cancer as a model for the development of personalized medicine:
What should you ask from your pathologist in order to apply specific treatments
|E. Felip, ES
|14:00||Future developments in medical lung cancer therapy
|L. Crinò, IT
||Clinical case discussion
|J. Remon, FR
|WHERE DO WE STAND IN PROSTATE CANCER?
|15:30||Genomic tools in prostate cancer
|D. Tilki, DE
||How to decide the medical treatment of prostate cancer?
|16:20||Discussion based on a clinical case
|N. Mottet, FR
|16:30||Genomics: An essential aspect for haemato-oncologists
|A. Stathis, CH
M. Aapro, CH - J. Gligorov, FR
|WHERE DO WE STAND IN COLORECTAL CANCER?
|8:30||Genomic tools in colorectal cancer
|N. Normanno, IT
|9:00||How does the clinician use these data to best treat colon and rectal cancer?
|9:20||Discussion based on a clinical case
|D. Arnold, DE
|WHERE DO WE STAND IN BREAST CANCER?
||Pathological characterisation of breast cancer: Bridges between molecular and pathological definitions (triple negative, liminal, lobular…)
|G. Viale, IT
|10:30||Molecular characterisation of breast cancer: When is it needed? Is lobular an unrecognized special case?
|F. Penault-Llorca, FR
|11:00||Neoadjuvant/adjuvant therapy: How to manage early triple-negative tumours with and without BRCA mutations|
|11:20||Discussion based on a clinical case
|L. Del Mastro, IT
||Treatment of HER-2 positive disease in the (neo-) adjuvant settings:
|11:50||Discussion based on a clinical case
|V. Dieras, FR
|12:00||What is or is not special about invasive lobular tumour adjuvant treatment
|12:20||Discussion based on a clinical case|
|G. Curigliano, IT
|M. Aapro, CH and J. Gligorov, FR
|12:45||Lunch and departures|